Artificial-intelligence evangelists such as Sam Altman want to reshape the world, but they need mountains of money to do it. That is sparking a modern-day gold rush on Wall Street.

There is no word yet on when the IPO will happen. According to Voyager, it is still working out "the number of shares to be ...

Saturday’s budget clarifies asset sales tax for domestic investors, potentially reducing litigation. This and more in today’s ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Private equity will have a more positive 2025 than it's had recent years, and institutional investors will likely turn their ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.

BloombergNEF says in a new report that global clean energy investment reached $2.1 trillion in 2024, more than doubling 2020 ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

A report on energy transition investments from BloombergNEF showed that global investment in clean energy technologies hit a ...

Shares in Venture Global are expected to make their debut on the New York Stock Exchange after the company raised $1.75 ...

Bond manager’s $7 billion stake in Venture Global latest sign that traditional asset managers are making inroads investing in ...